Erlotinib is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Aurobindo Pharma Limited. The primary component is Erlotinib Hydrochloride.
Product ID | 59651-531_3ecafc1e-979a-4aff-a276-18fc0b110491 |
NDC | 59651-531 |
Product Type | Human Prescription Drug |
Proprietary Name | Erlotinib |
Generic Name | Erlotinib |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2022-06-22 |
Marketing Category | ANDA / |
Application Number | ANDA216342 |
Labeler Name | Aurobindo Pharma Limited |
Substance Name | ERLOTINIB HYDROCHLORIDE |
Active Ingredient Strength | 100 mg/1 |
Pharm Classes | Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-06-22 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0093-7662 | Erlotinib | Erlotinib |
0093-7663 | Erlotinib | Erlotinib |
0093-7664 | Erlotinib | Erlotinib |
51991-890 | Erlotinib | Erlotinib Hydrochloride |
51991-891 | Erlotinib | Erlotinib Hydrochloride |
51991-892 | Erlotinib | Erlotinib Hydrochloride |
59651-530 | Erlotinib | Erlotinib |
59651-531 | Erlotinib | Erlotinib |
59651-532 | Erlotinib | Erlotinib |
59923-725 | Erlotinib | Erlotinib |
59923-726 | Erlotinib | Erlotinib |
59923-727 | Erlotinib | Erlotinib |
63304-095 | Erlotinib | Erlotinib |
63304-096 | Erlotinib | Erlotinib |
63304-135 | Erlotinib | Erlotinib |
68382-913 | Erlotinib | Erlotinib |
68382-914 | Erlotinib | Erlotinib |
68382-915 | Erlotinib | Erlotinib |
70771-1521 | Erlotinib | Erlotinib |
70771-1522 | Erlotinib | Erlotinib |
70771-1523 | Erlotinib | Erlotinib |
72485-217 | Erlotinib | Erlotinib hydrochloride |
72485-218 | Erlotinib | Erlotinib hydrochloride |
72485-219 | Erlotinib | Erlotinib hydrochloride |